uploads/2018/02/nerve-cell-2213009_1280.jpg

Analysts’ Ratings for Alkermes and Its Peers in February 2018

By

Updated

Company overview

Headquartered in Dublin, Ireland, Alkermes (ALKS) is an integrated biopharmaceutical company engaged in the research, development, and commercialization of pharmaceutical products. These products are intended to address medical needs in therapeutic areas of central nervous system (or CNS) disorders like schizophrenia, depression, addiction, and multiple sclerosis.

Some of Alekermes’ key marketed products are Vivitrol for alcohol and opioid dependence, Ampyra and Fampyra for multiple sclerosis, and Bydureon for type 2 diabetes. The company’s products for the treatment of schizophrenia include Aristada, Risperdal Consta, Invega Sustenna, Xeplon, Invega Trinza, and Trevicta.

Article continues below advertisement

Analysts’ recommendations

Of the 12 analysts covering Alkermes (ALKS) in February 2018, five analysts gave the stock a “buy” or a higher rating. Seven analysts gave it a “hold” rating. The mean rating for the stock is 2.5 with a target price of $61.58.

Peers’ ratings

Of the 22 analysts covering Merck & Co. (MRK) in February 2018, 13 analysts gave the stock a “buy” or a higher rating. Nine analysts gave it a “hold” rating. The mean rating for the stock is ~2.1 with a target price of $66.60.

Of the 23 analysts covering Pfizer (PFE) in February 2018, 12 analysts gave the stock a “buy” or a higher rating, nine analysts gave it a “hold” rating, and two analysts gave it a “sell” rating. The mean rating for the stock is ~2.6 with a target price of $40.00.

Of the six analysts covering Vanda Pharmaceuticals (VNDA) in February 2018, two analysts gave the stock a “strong buy” rating, and three analysts gave it a “buy” rating. Only one analyst gave the stock a “sell” rating. The mean rating for the stock is 2.0 with a target price of $20.50.

In the next part of this series, we’ll take a deeper look at Alkermes’ product portfolio

Advertisement

More From Market Realist